New prospective, multicenter study presented at smr demonstrates castle biosciences' decisiondx®-melanoma test provides significant risk prediction for patients with cutaneous melanoma, adding value to current stage-based treatment pathway decisions

Friendswood, texas--(business wire)---- $cstl #2024smrcongress--castle will present new data on decisiondx-melanoma and decisiondx-um at the 21st international congress of the society for melanoma research (smr).
CSTL Ratings Summary
CSTL Quant Ranking